Compare Nasdaq Inc (NDAQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs TG Therapeutics Inc — how do they compare? Nasdaq Inc trades at $94.62 (market cap $53.13B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Nasdaq Inc is far larger — about 6.2× TG Therapeutics Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NDAQ | TGTX | |
|---|---|---|
Market Cap | $53.13B | $8.53B |
Sector | Financials | Health |
52-Week High | $100.98 | $59.06 |
52-Week Low | $76.85 | $26.94 |
Enterprise Value | $59.58B | $8.74B |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.04, down 1.9% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding the $0.984 estimate. Revenue grew to $8.26B in 2025, up from $7.4B in 2024, and net income margin improved to 22.52%. Recent news highlights Nasdaq's acquisition of Dasseti to enhance AI capabilities in investment technology.
The outlook for NDAQ is positive, supported by consistent earnings outperformance, revenue growth, and strategic acquisitions. Risks include market volatility and competitive pressures. Analysts maintain a bullish consensus with a $109.20 price target, implying 15% upside from current levels.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
